New imaging agent aims to spot Hard-to-Find cancers
NCT ID NCT07052760
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 37 times
Summary
This study was designed to test a new imaging agent called 111In-ABD147 that targets a protein (DLL3) found on many solid tumors, including prostate cancer and neuroendocrine tumors. The goal was to see if SPECT scans using this agent could better detect cancer that has spread. The study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.